Magoneko Solutions Co., Ltd. (headquartered in Nishi-ku, Yokohama; Minoru Takada, Representative Director and President; hereinafter "Magoneko") and Richmond Pharmacology Limited (headquartered in London, UK, CEO: Dr. Jorg Taubel, hereinafter referred to as "Richmond Pharmacology") signed an agreement on August 1st regarding collaboration in business development in Japan.

Richmond Pharmacology has over 20 years of experience in conducting more than 100 Phase-I trials in London with Japanese volunteers, and is a very unique CRO with the largest Japanese database (24,000 people) of any facility based in Europe, and has a track record of being used by many customers, mainly those planning international joint clinical trials. In addition, recently, the proportion of trials conducted on specific patient cohorts accounts for about 60% of the total number of trials, and the company is also focusing on clinical trials in the fields of gene silencing and gene editing, and is working hard to accelerate research using adaptive designs and provide "Faster Answers" while accurately grasping the needs of the times.

Richmond Pharmacology provides early clinical trial services, including Japanese participants, at its Phase 1 facility in London to Japanese pharmaceutical and biotech companies, making it easier for Japan to participate in clinical trials from Phase 2 onwards, and we believe this will lead to the elimination of drug lag and drug loss, which are issues in Japan.

For inquiries regarding this matter, please use the inquiry form.